Idera Pharmaceuticals Inc. (IDRA)

6.58
0.10 1.50
NASDAQ : Health Technology
Prev Close 6.68
Open 6.72
Day Low/High 6.54 / 7.00
52 Wk Low/High 5.20 / 20.40
Volume 47.46K
Avg Volume 237.20K
Exchange NASDAQ
Shares Outstanding 27.18M
Market Cap 183.74M
EPS -3.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Idera Pharmaceuticals Announces Launch Of Global Phase 3 Trial Evaluating IMO-2125 In Combination With Ipilimumab For The Treatment Of Anti-PD-1 Refractory Melanoma (ILLUMINATE 301)

Idera Pharmaceuticals Announces Launch Of Global Phase 3 Trial Evaluating IMO-2125 In Combination With Ipilimumab For The Treatment Of Anti-PD-1 Refractory Melanoma (ILLUMINATE 301)

- Clinical trial targeting enrollment of approximately 300 anti-PD-1 refractory melanoma patients at approximately 80 global trial sites - 

Commit To Buy Idera Pharmaceuticals At $2, Earn 35.1% Annualized Using Options

Commit To Buy Idera Pharmaceuticals At $2, Earn 35.1% Annualized Using Options

Investors considering a purchase of Idera Pharmaceuticals Inc stock, but cautious about paying the going market price of $1.99/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $2 strike, which has a bid at the time of this writing of 35 cents.

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Concerning Whether The Sale Of Idera Pharmaceuticals, Inc. To BioCryst Pharmaceuticals, Inc. Is Fair To Shareholders

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Concerning Whether The Sale Of Idera Pharmaceuticals, Inc. To BioCryst Pharmaceuticals, Inc. Is Fair To Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Provides 2018 Update And Outlook

Idera Pharmaceuticals Provides 2018 Update And Outlook

Company to Present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 11:00 AM PT/2:00 PM ET

Short Interest Decreases By 64.5% For IDRA

Short Interest Decreases By 64.5% For IDRA

The most recent short interest data has been released for the 10/31/2017 settlement date, which shows a 5,553,069 share decrease in total short interest for Idera Pharmaceuticals Inc , to 3,061,046, a decrease of 64.46% since 10/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Short Interest In Idera Pharmaceuticals Falls 13.5%

Short Interest In Idera Pharmaceuticals Falls 13.5%

The most recent short interest data has been released for the 10/13/2017 settlement date, which shows a 1,345,734 share decrease in total short interest for Idera Pharmaceuticals Inc , to 8,614,115, a decrease of 13.51% since 09/29/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

First Week of IDRA May 2018 Options Trading

First Week of IDRA May 2018 Options Trading

Investors in Idera Pharmaceuticals Inc saw new options become available this week, for the May 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Achillion Shares Are Plunging on Termination of Hepatitis C Pact

Achillion Shares Are Plunging on Termination of Hepatitis C Pact

The New Haven, Conn.-based firm on Sept. 9 received a termination notice regarding its license and collaboration pact with Johnson & Johnson's Janssen Pharmaceuticals Inc. on hepatitis C.

Idera Pharmaceuticals Presents Pre-Clinical Data From IMO-2125 Treatment In Combination With Ipilimumab That Demonstrates Induction Of Durable Anti-tumor Responses Associated With Tumor-Specific Memory

Idera Pharmaceuticals Presents Pre-Clinical Data From IMO-2125 Treatment In Combination With Ipilimumab That Demonstrates Induction Of Durable Anti-tumor Responses Associated With Tumor-Specific Memory

Clinical Data from Ongoing Phase 1/2 Trial of IMO-2125 in anti-PD-1 Refractory Melanoma to be presented Sunday, September 10 at the European Society for Medical Oncology Congress (ESMO) in Madrid, Spain

Idera Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides Corporate Update

Idera Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides Corporate Update

IMO-2125 Clinical Trial Data Update at ESMO in September

TheStreet Quant Rating: D (Sell)